Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial

Giovanni Scambia, Maria Gabriella Ferrandina, Domenica Lorusso, Stefano Greggi, Vanda Salutari, Francesco Legge, S Pignata, A Savarese, R Sorio, E Breda, V Gebbia, Patrizia Musso, L Frigerio, Av Lombardi, A Febbraro, P Del Medico, A Ferro, P Scollo, S Tamberi, A BrandesA Ravaioli, Mr Valerio, E Aitini, Davide Natale, L Scaltriti, C Pisano, M Di Maio, Antonio Morabito, C Gallo, Francesca Perrone

Risultato della ricerca: Contributo in rivistaArticolo in rivista

131 Citazioni (Scopus)

Abstract

Carboplatin/paclitaxel is the standard first-line chemotherapy for patients with advanced ovarian cancer. Multicentre Italian Trials in Ovarian Cancer-2 (MITO-2), an academic multicenter phase III trial, tested whether carboplatin/pegylated liposomal doxorubicin (PLD) was more effective than standard chemotherapy.
Lingua originaleEnglish
pagine (da-a)3628-3635
Numero di pagine8
RivistaJournal of Clinical Oncology
Volume29
DOI
Stato di pubblicazionePubblicato - 2011

Keywords

  • Adult
  • Aged
  • Antineoplastic Agents
  • Antineoplastic Combined Chemotherapy Protocols
  • Carboplatin
  • Disease-Free Survival
  • Doxorubicin
  • Female
  • Humans
  • Middle Aged
  • Ovarian Neoplasms
  • Polyethylene Glycols
  • Quality of Life

Fingerprint

Entra nei temi di ricerca di 'Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial'. Insieme formano una fingerprint unica.

Cita questo